JPH06312934A - Production of substance having immunosuppressive effect - Google Patents
Production of substance having immunosuppressive effectInfo
- Publication number
- JPH06312934A JPH06312934A JP5104750A JP10475093A JPH06312934A JP H06312934 A JPH06312934 A JP H06312934A JP 5104750 A JP5104750 A JP 5104750A JP 10475093 A JP10475093 A JP 10475093A JP H06312934 A JPH06312934 A JP H06312934A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- maitake
- immunosuppressive effect
- immunosuppressive
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 28
- 230000001506 immunosuppresive effect Effects 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 17
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 17
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 241000222684 Grifola Species 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 4
- 238000011735 C3H mouse Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 244000097863 Grifola umbellata Species 0.000 description 1
- 235000002897 Grifola umbellata Nutrition 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明はマイタケの菌糸体若しく
は子実体から抽出する免疫抑制効果を有する物質を製造
する方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing a substance having an immunosuppressive effect, which is extracted from mycelium or fruiting body of Maitake mushroom.
【０００２】[0002]
【従来の技術及び発明が解決しようとする課題】従来か
らマイタケの菌糸体若しくは子実体から抽出したβ−
１，６結合を主鎖とし、１，３の分岐鎖結合を有する多
糖体が、経口投与のみならず、皮下，腹腔内投与いずれ
によっても免疫賦活化作用を示すことが知られている。PRIOR ART AND PROBLEM TO BE SOLVED BY THE INVENTION Conventionally, β-extracted from mycelium or fruiting body of Maitake
It is known that a polysaccharide having a 1,6 bond as a main chain and a 1,3 branched chain bond exhibits an immunostimulating action not only by oral administration but also by subcutaneous or intraperitoneal administration.
【０００３】ところで、本発明者は更に研究した結果、
上記免疫賦活化作用とは反対の顕著な免疫抑制作用を発
揮する物質がマイタケの菌糸体若しくは子実体から生成
し得ることを見出し、本発明を完成させた。By the way, as a result of further research by the inventor,
The present inventors have found that a substance exhibiting a remarkable immunosuppressive action opposite to the above-mentioned immunostimulatory action can be produced from mycelium or fruiting body of Maitake mushroom, and completed the present invention.
【０００４】[0004]
【課題を解決するための手段】添付図面を参照して本発
明の要旨を説明する。The gist of the present invention will be described with reference to the accompanying drawings.
【０００５】免疫抑制剤として使用する物質の製造方法
であって、マイタケの菌糸体若しくは子実体から抽出す
ることを特徴とする免疫抑制効果を有する物質の製造方
法に係るものである。The present invention relates to a method for producing a substance to be used as an immunosuppressant, which comprises extracting from a mycelium or fruiting body of Maitake mushrooms and having an immunosuppressive effect.
【０００６】マイタケの菌糸体若しくは子実体を熱水で
抽出することを特徴とする免疫抑制効果を有する物質の
製造方法に係るものである。[0006] The present invention relates to a method for producing a substance having an immunosuppressive effect, which comprises extracting mycelium or fruiting body of Maitake mushroom with hot water.
【０００７】マイタケの菌糸体若しくは子実体を熱水処
理して得られる可溶性画分にアルコールを添加し、これ
を所定時間放置した後、該液中の画分を収集し、該画分
を水に溶解させることで生成せしめることを特徴とする
免疫抑制効果を有する物質の製造方法に係るものであるAlcohol was added to the soluble fraction obtained by treating the mycelium or fruiting body of Maitake mushroom with hot water, and the mixture was allowed to stand for a predetermined time. Then, the fraction in the liquid was collected, and the fraction was washed with water. The present invention relates to a method for producing a substance having an immunosuppressive effect, which is characterized in that it is produced by dissolving it in
【０００８】[0008]
【実施例】マイタケ（マイタケ、白マイタケ、チョレイ
マイタケのいずれでも良い。）の菌糸体若しくは子実体
５００ｇを熱水１ｌで抽出（６０〜１２５°Ｃ、３〜１
０時間）して得られた可溶性画分５０〜８０ｇに、エタ
ノール（メタノールでも良い。）を２０〜８０％の濃度
（重量濃度）になるよう添加し、低温下（０〜１５°
Ｃ）で数時間放置する。液面或いは液中に浮遊または壁
面に付着する画分４０〜５０ｇを集め、これを蒸留水２
００ｍｌに溶解させる。[Example] 500 g of mycelium or fruiting body of Maitake (any of Maitake, White Maitake and Chorei Maitake) may be extracted with 1 liter of hot water (60-125 ° C, 3-1).
Ethanol (or methanol may be used) is added to 50 to 80 g of the soluble fraction obtained after 0 hours) so as to have a concentration (weight concentration) of 20 to 80%, and the mixture is kept at low temperature (0 to 15 °).
Leave at C) for several hours. Collect 40 to 50 g of the fraction floating on the liquid surface or in the liquid or adhering to the wall surface, and collect this with distilled water 2
Dissolve in 00 ml.
【０００９】尚、抽出に際してアルコールを使用するこ
とで該アルコールに溶出する物質を抽出している。即
ち、抽出物質は脂質が主体となる物質である為抽出に際
してアルコールを使用している。It should be noted that a substance that dissolves in the alcohol is extracted by using an alcohol during the extraction. That is, since the extracted substance is a substance mainly composed of lipid, alcohol is used for extraction.
【００１０】この物質はアンスロン反応およびニンヒド
リン反応のいずれにも陽性であり、糖−タンパク複合体
である。This substance is positive for both anthrone reaction and ninhydrin reaction, and is a sugar-protein complex.
【００１１】多糖とタンパクの比率（重量比）は９７：
３から５５：４５の範囲を示すが、９０：１０の物が主
成分として得られる。The ratio of polysaccharide to protein (weight ratio) is 97:
A range of 3 to 55:45 is shown, but a 90:10 product is obtained as the main component.
【００１２】この物質（多糖体）をメチル化してその構
造を検討したところ、β−１，６を主鎖とし、１.４の
分枝鎖を持つもの及びβ−１，３を主鎖とし、１，４の
分枝鎖を持つものが各々得られた。[0012] When this substance (polysaccharide) was methylated and its structure was examined, it was found that β-1,6 had a main chain and a branched chain of 1.4 and β-1,3 had a main chain. , And 1,4 branched chains were respectively obtained.
【００１３】これらをＭＭ−４６ Carcinomaを移植した
Ｃ３Ｈマウスに０.０１mg〜１.０mg／kg体重当たりの量
で腹腔内投与を３〜１０回行い，腫瘍の増殖に及ぼす作
用を検討した。These were intraperitoneally administered to C3H mice transplanted with MM-46 Carcinoma in an amount of 0.01 mg to 1.0 mg / kg body weight 3 to 10 times, and the effect on tumor growth was examined.
【００１４】更に、ウィン・アッセイを行い，免疫系の
活性度について調べると共に各種免疫担当細胞に及ぼす
影響について解明した。Furthermore, a Win assay was carried out to examine the activity of the immune system and elucidate the effect on various immunocompetent cells.
【００１５】ＭＭ−４６ Carcinomaの増殖に及ぼす抽出
物質の腹腔内投与結果を表１に示す。Table 1 shows the results of intraperitoneal administration of the extract on the growth of MM-46 Carcinoma.
【００１６】[0016]
【表１】 [Table 1]
【００１７】明らかに、抽出物質の投与により腫瘍の増
殖抑制作用は阻害され、固形腫瘍の重量は、処理群の方
が無処理群に比べ重かった。このことは腫瘍免疫作用が
抑制されたことを示すものである。そこでウィン・アッ
セイを行い、この事実を確認した。Apparently, the tumor growth inhibitory effect was inhibited by the administration of the extracted substance, and the weight of the solid tumor was higher in the treated group than in the untreated group. This indicates that the tumor immunity was suppressed. Therefore, a Win assay was conducted to confirm this fact.
【００１８】即ち、ＭＭ−４６ Carcinomaを移植し
（(i)生理食塩水或いは(ii)抽出物質を腹腔内投与し
た。）、１５日目のＣ３Ｈマウスから脾臓を取り出し、
夫々脾細胞を調整した。これらの脾細胞にＭＭ−４６ C
arcinoma細胞を混じ、正常Ｃ３Ｈマウスに移植し、１５
日目に増殖した腫瘍重量を測定した。表２にその結果を
示す。That is, MM-46 Carcinoma was transplanted ((i) physiological saline or (ii) extract substance was intraperitoneally administered), and the spleen was taken out from the C3H mouse on the 15th day.
The splenocytes were prepared respectively. MM-46 C in these splenocytes
15 mixed with arcinoma cells and transplanted into normal C3H mice,
The tumor weight grown on the day was measured. The results are shown in Table 2.
【００１９】[0019]
【表２】 [Table 2]
【００２０】表２に示す如く、抽出物質の投与により抑
制作用はまったく認められず、逆に増殖の促進が見られ
た。すなわち、担ガンマウスから得た脾細胞と癌細胞を
混じ正常マウスに移植したところ、担ガン化により免疫
力を得た脾細胞の作用により癌の増殖が約５０％程度抑
制されているのに対し、抽出物質の投与によりこの脾細
胞の免疫作用が抑制された。このことは、癌の増殖が促
進されることを示すものである。As shown in Table 2, the inhibitory effect was not observed at all by the administration of the extract substance, and conversely the promotion of growth was observed. That is, when spleen cells obtained from cancer-bearing mice and cancer cells were mixed and transplanted to normal mice, the growth of cancer was suppressed by about 50% by the action of spleen cells that gained immunity due to canceration. On the other hand, the administration of the extract substance suppressed the immune action of the splenocytes. This indicates that the growth of cancer is promoted.
【００２１】即ち、抽出物質によって免疫抑制、つまり
サプレッサーＴ細胞の活性が促進され、癌免疫作用の阻
止が起こるものと認めた。That is, it was confirmed that the extracted substance promotes immunosuppression, that is, the activity of suppressor T cells, resulting in the inhibition of cancer immunity.
【００２２】乾燥及び生マイタケから得られる多糖体を
主とし、これにタンパク質が結合した多糖−タンパク複
合体（β−１，３、β−１，６、β−１，４を主鎖と
し、分枝鎖を有する構造をもつ多糖体）は免疫抑制作用
を示すことが認められた。Polysaccharides obtained from dried and fresh Maitake mushrooms are mainly used, and a polysaccharide-protein complex (β-1,3, β-1,6, β-1,4 having a main chain as a protein bound thereto, It was confirmed that a polysaccharide having a structure having a branched chain has an immunosuppressive action.
【００２３】この免疫抑制はサプレサーＴ細胞の活性化
やマクロファージの活性抑制などに由来すると推察さ
れ、その結果、癌免疫作用をも阻害することが見出され
た。It was speculated that this immunosuppression was derived from activation of suppressor T cells, suppression of macrophage activity, etc., and as a result, it was also found to inhibit the cancer immunity.
【００２４】キノコの中にこの様な作用を持つ物質が存
在する報告は未だ認められず、本実施例に係る物質が移
植拒絶作用をはじめとする免疫抑制を必要とする場合、
非常に有用な新物質となる。No report has been found that a substance having such an action exists in mushrooms, and when the substance according to this example requires immunosuppression including transplant rejection,
It will be a very useful new substance.
【００２５】[0025]
【発明の効果】本発明は上述のようにしたから、秀れた
免疫抑制効果を有する物質を製造し得ることになる。As described above, the present invention makes it possible to produce a substance having an excellent immunosuppressive effect.
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成６年６月１６日[Submission date] June 16, 1994
【手続補正１】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】特許請求の範囲[Name of item to be amended] Claims
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【特許請求の範囲】[Claims]
【手続補正２】[Procedure Amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００６[Correction target item name] 0006
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【０００６】マイタケの菌糸体若しくは子実体から熱水
で抽出することを特徴とする免疫抑制効果を有する物質
の製造方法に係るものである。[0006] The present invention relates to a method for producing a substance having an immunosuppressive effect, which is characterized by extracting from a mycelium or fruiting body of Maitake mushroom with hot water.
【手続補正３】[Procedure 3]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００７[Correction target item name] 0007
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【０００７】マイタケの菌糸体若しくは子実体を熱水処
理して得られる可溶性画分にアルコールを添加し、これ
を所定時間放置した後、該液中の画分を収集し、該画分
を水に溶解させることで生成せしめることを特徴とする
免疫抑制効果を有する物質の製造方法に係るものであ
る。Alcohol was added to the soluble fraction obtained by treating the mycelium or fruiting body of Maitake mushroom with hot water, and the mixture was allowed to stand for a predetermined time. Then, the fraction in the liquid was collected, and the fraction was washed with water. The present invention relates to a method for producing a substance having an immunosuppressive effect, which is characterized in that the substance is produced by dissolving it in.
Claims (3)
法であって、マイタケの菌糸体若しくは子実体から抽出
することを特徴とする免疫抑制効果を有する物質の製造
方法。1. A method for producing a substance to be used as an immunosuppressant, which comprises extracting from a mycelium or fruiting body of Maitake mushrooms.
で抽出することを特徴とする免疫抑制効果を有する物質
の製造方法。2. A method for producing a substance having an immunosuppressive effect, which comprises extracting the mycelium or fruiting body of Maitake mushroom with hot water.
処理して得られる可溶性画分にアルコールを添加し、こ
れを所定時間放置した後、該液中の画分を収集し、該画
分を水に溶解させることで生成せしめることを特徴とす
る免疫抑制効果を有する物質の製造方法。3. A soluble fraction obtained by treating the mycelium or fruiting body of Maitake mushroom with hot water is added with alcohol and allowed to stand for a predetermined period of time, and then the fraction in the liquid is collected. A method for producing a substance having an immunosuppressive effect, characterized in that the substance is produced by dissolving it in water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5104750A JP2753935B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing immunosuppressant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5104750A JP2753935B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing immunosuppressant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06312934A true JPH06312934A (en) | 1994-11-08 |
| JP2753935B2 JP2753935B2 (en) | 1998-05-20 |
Family
ID=14389177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5104750A Expired - Lifetime JP2753935B2 (en) | 1993-04-30 | 1993-04-30 | Method for producing immunosuppressant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2753935B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06312938A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having promoting effect for hair tonicity |
| CN1120173C (en) * | 1996-03-08 | 2003-09-03 | 株式会社雪国梅泰克 | Anti-tumor substances extracted from tree flower fungus |
| JP2004331525A (en) * | 2003-05-01 | 2004-11-25 | Yukiguni Maitake Co Ltd | Neurotrophic factor-like action substance |
| EP2087899A4 (en) * | 2006-10-27 | 2010-04-07 | Yukiguni Maitake Co Ltd | ORIGINAL SUBSTANCE OF GRIFOLA FRONDOSA HAVING ACTIVITY AGAINST INFLUENZA VIRUS AND PROCESS FOR PRODUCTION THEREOF |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582583A (en) * | 2017-10-30 | 2018-01-16 | 无锡福祈制药有限公司 | The compound preparation of rejection after a kind for the treatment of organs transplanting |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52117493A (en) * | 1976-03-26 | 1977-10-01 | Kisaku Mori | Extraction of medically effective substance of mushroom |
| JPS589680A (en) * | 1981-07-07 | 1983-01-20 | Nippon Beet Sugar Mfg Co Ltd | Preparation of health nutrient drink containing culture fluid from fungus of genus grifola as principal constituent |
| JPS589681A (en) * | 1981-07-07 | 1983-01-20 | Nippon Beet Sugar Mfg Co Ltd | Preparation of health drink containing extract from fruit body |
| JPS59210901A (en) * | 1983-05-17 | 1984-11-29 | Nippon Kinoko Kenkyusho | Glucan having beta-1,6 bond-containing main chain, obtained from maitake and antineoplastic agent comprising same |
| JPS6058925A (en) * | 1983-09-09 | 1985-04-05 | Nippon Beet Sugar Mfg Co Ltd | Antitumor active substance |
| JPS60255733A (en) * | 1984-05-30 | 1985-12-17 | Nippon Beet Sugar Mfg Co Ltd | Beta-d-glucan |
| JPS62209091A (en) * | 1986-03-08 | 1987-09-14 | Nippon Beet Sugar Mfg Co Ltd | Antitumor active polysaccharide |
| JPH01228480A (en) * | 1988-03-09 | 1989-09-12 | Nippon Hai Potsukusu:Kk | Production of extract of cultured mycelia of edible basidiomycete |
| JPH05104797A (en) * | 1991-10-15 | 1993-04-27 | Tokyo Electric Co Ltd | Printer |
-
1993
- 1993-04-30 JP JP5104750A patent/JP2753935B2/en not_active Expired - Lifetime
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52117493A (en) * | 1976-03-26 | 1977-10-01 | Kisaku Mori | Extraction of medically effective substance of mushroom |
| JPS589680A (en) * | 1981-07-07 | 1983-01-20 | Nippon Beet Sugar Mfg Co Ltd | Preparation of health nutrient drink containing culture fluid from fungus of genus grifola as principal constituent |
| JPS589681A (en) * | 1981-07-07 | 1983-01-20 | Nippon Beet Sugar Mfg Co Ltd | Preparation of health drink containing extract from fruit body |
| JPS59210901A (en) * | 1983-05-17 | 1984-11-29 | Nippon Kinoko Kenkyusho | Glucan having beta-1,6 bond-containing main chain, obtained from maitake and antineoplastic agent comprising same |
| JPS6058925A (en) * | 1983-09-09 | 1985-04-05 | Nippon Beet Sugar Mfg Co Ltd | Antitumor active substance |
| JPS60255733A (en) * | 1984-05-30 | 1985-12-17 | Nippon Beet Sugar Mfg Co Ltd | Beta-d-glucan |
| JPS62209091A (en) * | 1986-03-08 | 1987-09-14 | Nippon Beet Sugar Mfg Co Ltd | Antitumor active polysaccharide |
| JPH01228480A (en) * | 1988-03-09 | 1989-09-12 | Nippon Hai Potsukusu:Kk | Production of extract of cultured mycelia of edible basidiomycete |
| JPH05104797A (en) * | 1991-10-15 | 1993-04-27 | Tokyo Electric Co Ltd | Printer |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06312938A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having promoting effect for hair tonicity |
| CN1120173C (en) * | 1996-03-08 | 2003-09-03 | 株式会社雪国梅泰克 | Anti-tumor substances extracted from tree flower fungus |
| JP2004331525A (en) * | 2003-05-01 | 2004-11-25 | Yukiguni Maitake Co Ltd | Neurotrophic factor-like action substance |
| EP2087899A4 (en) * | 2006-10-27 | 2010-04-07 | Yukiguni Maitake Co Ltd | ORIGINAL SUBSTANCE OF GRIFOLA FRONDOSA HAVING ACTIVITY AGAINST INFLUENZA VIRUS AND PROCESS FOR PRODUCTION THEREOF |
| US8168196B2 (en) | 2006-10-27 | 2012-05-01 | Yukiguni Maitake Co., Ltd. | Grifola frondosa-derived substance having anti-influenza virus activity and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2753935B2 (en) | 1998-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09238697A (en) | Antitumor substance extracted from Maitake | |
| JP2003520576A (en) | Method, method and composition for producing cholesterol-lowering agent from higher basidiomycetes mushroom | |
| JPS6356881B2 (en) | ||
| US4202885A (en) | Process for the preparation of anti-transplanted sarcoma 180 tumorigenic substances | |
| JP2011026525A (en) | Extraction method of polysaccharides mainly composed of β-glucan | |
| Bisko et al. | Effects of cultivation parameters on intracellular polysaccharide production in submerged culture of the edible medicinal mushroom Lentinula edodes. | |
| CA1088443A (en) | Method of producing polysaccharides | |
| US4461760A (en) | Anticancer drugs | |
| US4229570A (en) | Method of producing nitrogen-containing polysaccharides | |
| JP3444624B2 (en) | Highly branched β-glucan, its production method and use | |
| JP4032372B2 (en) | Anticancer substance | |
| EP0413053A1 (en) | Process for producing useful substance from edible basidiomycete mycelium | |
| Mori et al. | Antitumor activities of edible mushrooms by oral administration | |
| JPH06312934A (en) | Production of substance having immunosuppressive effect | |
| JP2000159808A (en) | Method for separating and purifying basidiomycota hypha extract | |
| Tarnowski et al. | Influence of genotype of host on regression of solid and ascitic forms of sarcoma 180 and effect of chemotherapy on the solid form | |
| JP4057107B2 (en) | Glucomannan isolated from cultured mycelium or culture filtrate of Himematsutake and an antitumor agent comprising the same as an active ingredient | |
| JPH05117303A (en) | Water-soluble polysaccharides derived from Physcomitrella patens and antitumor agent containing the water-soluble polysaccharides as a main agent | |
| JP2014221899A (en) | METHOD FOR EXTRACTING POLYSACCHARIDE COMPRISING β-GLUCAN AS MAIN COMPONENT | |
| KR101879506B1 (en) | Extracting method of beta-glucan from Phellinus baumii | |
| JP2007031665A (en) | Glycoprotein extracted from grifola frondosa | |
| JP2001240603A (en) | beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM | |
| ITO et al. | Effects of coriolan, an antitumor polysaccharide, produced by Coriolus versicolor Iwade | |
| JP2732008B2 (en) | Method for producing hair growth promoter | |
| JPH0248000B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100306 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110306 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130306 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140306 Year of fee payment: 16 |
|
| EXPY | Cancellation because of completion of term |